nLife Therapeutics names Errol B. De Souza executive chairman
Dr. De Souza was the president and chief executive officer of Biodel, a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes (March 2010 to January 2016).
From April 2003 to January 2009, Dr. De Souza was president and chief executive officer of Archemix Corporation, a biopharmaceutical company focused on oligonucleotide aptamer therapeutics. From September 2002 to March 2003, he was president and chief executive officer and a director of Synaptic Pharmaceuticals.
As a result of a merger effective March 2003, Synaptic Pharmaceuticals became a wholly-owned subsidiary of H. Lundbeck A/S, an international pharmaceutical company.
Prior to that (1998 – 2002), Dr. De Souza held senior management positions with Aventis, and its predecessor company Hoechst Marion Roussel Pharmaceuticals where he was senior vice president and site head of US Drug Innovation and Approval (R&D) with responsibilities for the discovery and development of drug candidates for central nervous system and immunological disorders through proof-of-concept (Phase 2) trials.
He was co-founder and executive vice president of R&D at Neurocrine Biosciences, Inc (1992 – 1998) and Head of CNS Diseases Research at DuPont Merck (1990 – 1992).
Dr. De Souza received his B.A. (Honors) in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine. He has edited 6 books and is an author or co-author of approximately 300 original articles, chapters or reviews and 300 abstracts.
His research has focused on the receptor mechanisms involved in coordinating brain-endocrine-immune responses to stress.
He is the recipient of numerous national and international awards including the 1990 Joseph Cochin Young Investigator Award of the Committee on Problems of Drug Dependence, the 1991 Jordi Folch-Pi Memorial Award of the American Society for Neurochemistry, the 1994 Curt Richter Award and the 2005 Service Award of the International Society of Psychoneuroendocrinology, the 1997 Daniel H. Efron Award of the American College of Neuropsychopharmacology and the 2005 Ernst & Young Entrepreneur of the Year (New England Biotech category).
Dr. De Souza has served on the faculty of several universities including The Johns Hopkins University School of Medicine, University of Pennsylvania School of Medicine, the University of California at San Diego and Rutgers University.
He serves or has served on several Editorial Boards and National Institutes of Health Committees as well as Board of Directors of several private and public companies including Bionomics Limited, Catalyst Biosciences, IDEXX Laboratories, Palatin Technologies, Neurocrine Biosciences, Synaptic Pharmaceuticals and Targacept, Inc.. ■
LATEST MOVES FROM Spain
- Ramón Aragonés new CEO of NH Hotel Group
- Abertis appoints Luis Fortuño and Enrico Letta as new directors
- Homaira Akbari joins the board of Banco Santander
- Sanifit appoints Preston S. Klassen chief medical officer
- Telefónica approves José María Álvarez-Pallete as executive chairman
More inside POST